|
|
Blood, 1 December 2004, Vol. 104, No. 12, pp. 3746-3753.
Prepublished online as a Blood First Edition Paper on August 10, 2004; DOI 10.1182/blood-2004-05-1941.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen speciesdependent DNA double-strand breaks
Michal O. Nowicki,
Rafal Falinski,
Mateusz Koptyra,
Artur Slupianek,
Tomasz Stoklosa,
Ewa Gloc,
Margaret Nieborowska-Skorska,
Janusz Blasiak, and
Tomasz Skorski
From the Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA; and the Department of Molecular Genetics, University of Lodz, Poland.
The oncogenic BCR/ABL tyrosine kinase induces constitutive DNA damage in Philadelphia chromosome (Ph)-positive leukemia cells. We find that BCR/ABL-induced reactive oxygen species (ROSs) cause chronic oxidative DNA damage resulting in double-strand breaks (DSBs) in S and G2/M cell cycle phases. These lesions are repaired by BCR/ABL-stimulated homologous recombination repair (HRR) and nonhomologous end-joining (NHEJ) mechanisms. A high mutation rate is detected in HRR products in BCR/ABL-positive cells, but not in the normal counterparts. In addition, large deletions are found in NHEJ products exclusively in BCR/ABL cells. We propose that the following series of events may contribute to genomic instability of Ph-positive leukemias: BCR/ABL ROSs oxidative DNA damage DSBs in proliferating cells unfaithful HRR and NHEJ repair.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Genetic rearrangements beget genomic instability
- Feyruz V. Rassool
Blood 2004 104: 3424-3425.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
D. H. Mak, W. D. Schober, W. Chen, M. Konopleva, J. Cortes, H. M. Kantarjian, M. Andreeff, and B. Z. Carter
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells
Mol. Cancer Ther.,
September 1, 2009;
8(9):
2509 - 2516.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Fernandes, M. M. Reddy, J. R. Gonneville, S. C. DeRoo, K. Podar, J. D. Griffin, D. M. Weinstock, and M. Sattler
BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair
Blood,
August 27, 2009;
114(9):
1813 - 1819.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Gao, A. Howard, K. Ban, and J. Chandra
Oxidative Stress Promotes Transcriptional Up-regulation of Fyn in BCR-ABL1-expressing Cells
J. Biol. Chem.,
March 13, 2009;
284(11):
7114 - 7125.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Quintas-Cardama and J. Cortes
Molecular biology of bcr-abl1-positive chronic myeloid leukemia
Blood,
February 19, 2009;
113(8):
1619 - 1630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Cramer, M. Nieborowska-Skorska, M. Koptyra, A. Slupianek, E. T. P. Penserga, C. J. Eaves, W. Aulitzky, and T. Skorski
BCR/ABL and Other Kinases from Chronic Myeloproliferative Disorders Stimulate Single-Strand Annealing, an Unfaithful DNA Double-Strand Break Repair
Cancer Res.,
September 1, 2008;
68(17):
6884 - 6888.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sallmyr, A. E. Tomkinson, and F. V. Rassool
Up-regulation of WRN and DNA ligase III{alpha} in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks
Blood,
August 15, 2008;
112(4):
1413 - 1423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Stoklosa, T. Poplawski, M. Koptyra, M. Nieborowska-Skorska, G. Basak, A. Slupianek, M. Rayevskaya, I. Seferynska, L. Herrera, J. Blasiak, et al.
BCR/ABL Inhibits Mismatch Repair to Protect from Apoptosis and Induce Point Mutations
Cancer Res.,
April 15, 2008;
68(8):
2576 - 2580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. V. Rassool, T. J. Gaymes, N. Omidvar, N. Brady, S. Beurlet, M. Pla, M. Reboul, N. Lea, C. Chomienne, N. S.B. Thomas, et al.
Reactive Oxygen Species, DNA Damage, and Error-Prone Repair: A Model for Genomic Instability with Progression in Myeloid Leukemia?
Cancer Res.,
September 15, 2007;
67(18):
8762 - 8771.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Rink, A. Slupianek, T. Stoklosa, M. Nieborowska-Skorska, K. Urbanska, I. Seferynska, K. Reiss, and T. Skorski
Enhanced phosphorylation of Nbs1, a member of DNA repair/checkpoint complex Mre11-RAD50-Nbs1, can be targeted to increase the efficacy of imatinib mesylate against BCR/ABL-positive leukemia cells
Blood,
July 15, 2007;
110(2):
651 - 660.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. S. Rodrigues and M. Sattler
Chronic Myelogenous Leukemia Progenitors Display a Genetically Unstable Personality
J Natl Cancer Inst,
May 2, 2007;
99(9):
662 - 663.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Yoshida, F. Yoshida, D. E. Sears, S. M. Hart, D. Ikebe, A. Muto, S. Basu, K. Igarashi, and J. V. Melo
Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1
Blood,
February 1, 2007;
109(3):
1211 - 1219.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Wolanin, A. Magalska, G. Mosieniak, R. Klinger, S. McKenna, S. Vejda, E. Sikora, and K. Piwocka
Curcumin Affects Components of the Chromosomal Passenger Complex and Induces Mitotic Catastrophe in Apoptosis-Resistant Bcr-Abl-Expressing Cells
Mol. Cancer Res.,
July 1, 2006;
4(7):
457 - 469.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Koptyra, R. Falinski, M. O. Nowicki, T. Stoklosa, I. Majsterek, M. Nieborowska-Skorska, J. Blasiak, and T. Skorski
BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance
Blood,
July 1, 2006;
108(1):
319 - 327.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. G. Jorgensen, M. Copland, E. K. Allan, X. Jiang, A. Eaves, C. Eaves, and T. L. Holyoake
Intermittent Exposure of Primitive Quiescent Chronic Myeloid Leukemia Cells to Granulocyte-Colony Stimulating Factor In vitro Promotes their Elimination by Imatinib Mesylate
Clin. Cancer Res.,
January 15, 2006;
12(2):
626 - 633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Wiesner, J. M. Jones, D. E. Hasz, and D. A. Largaespada
Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse
Blood,
August 1, 2005;
106(3):
1054 - 1062.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. L. Komarova and D. Wodarz
Drug resistance in cancer: Principles of emergence and prevention
PNAS,
July 5, 2005;
102(27):
9714 - 9719.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|